Phase 1b: Multiple Ascending Dose Study (NCT03014609) Study Title: "Safety, Tolerability, PK and PD of Multiple Doses of Cagrilintide in Subjects With Type 2 Diabetes" Status: Completed Phase: Phase 1b Enrollment: 56 participants with T2D Study Period: 2017-2018 Design: Randomized, double-blind, placebo-controlled Duration: 12 weeks Dose Range: 0.3-4.5 mg SC weekly Population: T2D, BMI 25-40, HbA1c 7-10% Key Results: Weight Loss: 6.0 kg (4.5 mg dose) vs
The comprehensive recovery stack For maximum recovery support, some practitioners recommend a multi-peptide approach that addresses all major healing pathways simultaneously
Treatment Options for PCOS While there is no one standard medical advice for PCOS, medical treatments often focus on treating the symptoms such as acne, facial/body hair, irregular periods and fertility treatments
Excessive Se intake can lead to adverse health problems and Se toxicity
Do not wash your face for the first 6 hours
Renowned plastic surgeon Dr